Protein-based therapeutics are often limited by their short half-life in vivo and required repeat infusions to maintain therapeutic efficacy. Here, Zhang et al. address this challenge by engineering long-lived CAR T cells that can deliver biologics and persist in vivo for months from a single infusion.
- Guangyue Zhang
- Na Yin
- Min Peng
